On Sept. 29, 2020, Regeneron announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 showing it reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. REGN-COV2 also showed positive trends in reducing medical visits. The ongoing, randomized, double-blind trial measured the effect of adding REGN-COV2 to usual standard-of-care, compared to adding placebo to standard-of-care.